首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1983212

呼吸系统药物市场：依药物类别、应用、通路和地区划分。

Pulmonary Drugs Market, By Drug Class, By Application, By Distribution Channel, By Geography

出版日期: 2026年02月10日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2026年呼吸系统药物市场规模估计为566亿美元，预计2033年将达到965亿美元。预计2026年至2033年，该市场将以8.1%的复合年增长率成长。

分析范围		分析详情
基准年	2025	市场规模（2026 年）	566亿美元
效能数据	2020-2024	预测期	2026-2033
预测期（2026-2033 年）复合年增长率	8.10%	预计金额（2033 年）	965亿美元

呼吸系统药物用于治疗肺部疾病。它们适用于多种病症，从普通感冒等轻微疾病到气喘等慢性疾病。这些药物有多种剂型，包括口服片剂、口服溶液、注射剂和吸入剂。吸入剂可将药物直接输送到肺部，直接作用于肺组织，以最大限度地减少全身副作用。

市场动态

推动呼吸系统药物市场成长的关键因素包括慢性呼吸道疾病盛行率的上升、吸烟以及政府和非政府组织的各项措施。根据美国疾病管制与预防中心 (CDC) 统计，2015 年美国有 2500 万人患有气喘，这意味着每 13 个美国人中就有 1 人患有气喘。在 18 岁以下族群中，气喘患者达 620 万人次。每年，因气喘就诊的医师人数达 1,420 万人次，急诊就诊人数达 180 万人次。此外，品牌药专利到期、研发投入增加以及创新产品的上市预计将成为预测期内市场成长的主要驱动因素。例如，2017 年，葛兰素史克 (GSK) 的专利三联吸入剂 Trelegy Ellipta 获得美国食品药物食品药物管理局)核准，用于治疗慢性肺部疾病。 Trelegy Ellipta 将三种治疗方法整合到一个吸入器中，为患者提供了一种新的治疗选择。然而，大量未确诊的患者以及使用这些药物可能产生的副作用（如肾损伤和其他不良后果）预计将限制市场成长。

本报告的主要特点

本报告对全球呼吸系统药物市场进行了详细分析，包括预测期（2026-2033 年）的市场规模和复合年增长率，以 2025 年为基准年。
此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本节根据以下参数介绍全球呼吸系统药物市场主要企业的概况：公司概况、产品系列、主要亮点、财务绩效和策略。
本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
《全球呼吸系统药物市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过分析全球呼吸系统药物市场中使用的各种策略矩阵来促进决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
非洲
- 北非
- 中非
- 南非

第八章竞争情势

热图分析
市占率分析（3x3矩阵）
公司简介
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici SpA
- Zambon Company SpA
- Alaxia SAS
- Merck Sharp &Dohme Limited

第九章

参考
分析方法

简介目录

Product Code: CMI1285

Pulmonary Drugs Market is estimated to be valued at USD 56.6 Bn in 2026 and is expected to reach USD 96.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 56.6 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.10%	2033 Value Projection:	USD 96.5 Bn

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.

Key features of the study

This report provides in-depth analysis of pulmonary drugs market and provides market size (USD Bn) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2026 - 2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pulmonary drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Short Acting Beta-2 Agonists
- Others
Application Insights (Revenue, USD Bn, 2026 - 2033)
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZenca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi farmaceutici S.p.A.
- Zambon Company S.p.A.
- Alaxia SAS
- Merck Sharp & Dohme Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Pipeline Analysis
Promotional Activities and Campaigns
Supply Chain Analysis
PEST Analysis
Epidemiology

4. Global Pulmonary Drugs Market, By Drug Class, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Inhaled Corticosteroids
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Long Acting Beta-2 Agonists
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Antihistamines
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Vasodilators
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Short Acting Beta-2 Agonists
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Pulmonary Drugs Market, By Application, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Asthma & COPD
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Allergic Rhinitis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pulmonary Arterial Hypertension
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cystic Fibrosis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Pulmonary Drugs Market, By Distribution Channel, 2026 - 2033, (USD Bn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
E-Commerce
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Pulmonary Drugs Market, By Region, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - UK
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
- Sanofi SA
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Meda Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Circassia Pharmaceuticals Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- AstraZeneca Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- GlaxoSmithKline Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Mallinckrodt Pharmaceuticals Plc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Cheisi Farmaceutici S.p.A
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Zambon Company S.p.A
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Alaxia SAS
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
- Merck Sharp & Dohme Limited
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Future Plans
  - Analyst Views

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

呼吸系统药物市场：依药物类别、应用、通路和地区划分。

Pulmonary Drugs Market, By Drug Class, By Application, By Distribution Channel, By Geography

市场动态